Draflazine

Drug Profile

Draflazine

Alternative Names: R 70380

Latest Information Update: 11 Jun 2000

Price : $50

At a glance

  • Originator Janssen L.P.
  • Developer Janssen L.P.; Nonindustrial source
  • Class Antiplatelets; Piperazines
  • Mechanism of Action Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Ischaemic heart disorders; Thrombosis

Most Recent Events

  • 11 Jun 2000 Discontinued-Preclinical for Thrombosis in Belgium (Unknown route)
  • 11 Jun 2000 Discontinued-Preclinical for Ischaemic heart disorders in Norway (Unknown route)
  • 11 Jun 2000 Discontinued-Clinical for Ischaemic heart disorders in Netherlands (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top